APA (7th ed.) Citation

KC, G., N, K., A, G., L, O., A, I., & R, E. (2026). Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 67(6), 936. https://doi.org/10.2967/jnumed.125.271825

Chicago Style (17th ed.) Citation

KC, Gogebakan, Kunst N, Ghodsi A, Owens L, Iravani A, and Etzioni R. "Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 67, no. 6 (2026): 936. https://doi.org/10.2967/jnumed.125.271825.

MLA (9th ed.) Citation

KC, Gogebakan, et al. "Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 67, no. 6, 2026, p. 936, https://doi.org/10.2967/jnumed.125.271825.